Sarcopenia Treatment Market is segmented by Product Type (Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement, and Others), by Distribution Channel Type (Hospital Pharmacies, Retail Pharmacies, E-Commerce), Region (North America [The USA, Canada, and Mexico], Europe [Germany, France, The U.K., Russia, and Rest of Europe], Asia-Pacific [China, Japan, India, South Korea, and Rest of Asia-Pacific], and Rest of the World [Brazil, Saudi Arabia, Israel, and Others]).
Sarcopenia Treatment Market is segmented by Product Type (Protein Supplement, Vitamin B12 Supplement, Vitamin D & Calcium Supplement, and Others), by Distribution Channel Type (Hospital Pharmacies, Retail Pharmacies, E-Commerce), Region...
The sarcopenia treatment market was estimated at US$ 2.71 billion in 2021 and is expected to grow at a CAGR of 5.18% during 2022-2028 to reach US$ 3.9 billion in 2028.
Want to know more about the market scope:
Market Dynamics:
The COVID-19 outbreak had an influence on the sarcopenia treatment market since healthcare services were drastically reduced due to the social distancing measures implemented by governments worldwide. Furthermore, the COVID-19 pandemic had a considerable impact on the functioning of general hospital treatment for non-COVID-19 patients in hospitals around the world.
An article published in the Journal of Clinical Medicine in November 2021 titled "Skeletal Muscle Mass, Sarcopenia, and Rehabilitation Outcomes in Post-Acute COVID-19 Patients" discussed the impact of sarcopenia on such admission to a post-acute COVID-19 patient rehabilitation center on body composition and functional as well as respiratory capacity at discharge. According to the article, around 58% of COVID-19 patients at rehabilitation institutions had sarcopenia.
Malnutrition, elevated protein and energy requirements, weight loss, extended immobilisation, low-calorie and low-protein diet, low vitamin D level, inflammatory condition, BMI, and age are all factors that contribute to the disease's onset. Despite the study's small sample size and the need for more studies, early detection of sarcopenia may aid in disease management in COVID-19 patients.
As a result of the aforementioned considerations, COVID-19 has had an impact on the sarcopenia treatment industry. As a result, the researched market has shown modest expansion over time. The lack of new medications, on the other hand, severely limits market expansion.
Protein supplementation combined with exercise provides additional benefits on lower-extremity strength in healthy older adults with sarcopenia in Asian countries, according to a study published in March 2022 labelled "Effects of Protein Supplementation and Exercise on Delaying Sarcopenia in Healthy Older Individuals in Asian And Non-Asian Countries: A Systematic Review and Meta-Analysis." In addition, MYOS CORP acquired a patent from the United States Patent and Trademark Office (USPTO) in February 2021 titled "Methods and Compositions for Improving Skeletal Muscle Protein Fractional Synthetic Rate." This patent is expected to protect innovative technology related to increasing skeletal muscle protein synthesis rate in older mammals by the administration of patented nutritious compositions such as MYOS' advanced nutrition product, Fortetropin. Such patent filing will boost research activity in the sector, hence encouraging growth.
Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market. Some of them are:
The market is predicted to expand because to the growing geriatric population, as the likelihood of muscle weakness increases with age. According to CDPAP.com data updated in December 2021, the probability of disability in older persons with sarcopenia is 1.5 to 4.6 times higher than in older adults without sarcopenia.
According to World Population Prospects: the 2021 Revision, By 2030, one in every six persons on the planet will be 60 or older. At this point, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of adults aged 60 and up will have doubled (2.1 billion).
The number of people aged 80 and more is predicted to treble between 2020 and 2050, reaching 426 million. As a result of the growing ageing population and increased interest in preventative healthcare, supplement usage is increasing, which is a major reason in increasing demand for sarcopenia treatment.
Key Players
The following are the major players in the sarcopenia treatment market:
GlaxoSmithKline plc
Nestle Health Science
Sanofi S.A.
Bayer AG
Novartis AG
Cadila Healthcare Ltd
Eli Lilly and Company
To improve product penetration, prominent producers in the sarcopenia treatment market have focused on creative marketing and sales methods. In addition, the growing preference for online distribution methods has played an important impact. GlaxoSmithKline plc, Eli Lilly and Company, Nestlé S.A., Sanofi S.A., and Bayer AG are a few prominent market players in the studied market.
For instance:
MyMD Pharmaceuticals announced positive clinical findings in February 2022, prior to the next Phase II Trial of MYMD-1 therapeutic candidates. MYMD-1 is a revolutionary immunotherapy medicine that was created to reduce the ageing process, prevent sarcopenia and frailty, and extend healthy lifespan.
The United States Patent and Trademark Office granted MyMD Pharmaceuticals, Inc. the United States Patent 11,219,620 B2, titled "Method of Treating Sarcopenia." in January 2022. (USPTO). This new patent expands MyMD's intellectual property portfolio, which now includes 16 granted patents covering MYMD-1 in methods of reversing the normal ageing process and extending lifespan, as well as treating chronic inflammation, autoimmune disorders, diabetes, multiple sclerosis (MS), viral infections, addictions, fibrosis, asthma, and other disorders. As a result of the aforementioned reasons and recent advancements, the studied market is expected to expand in the area throughout the forecast period.
Segment Analysis
Product Type
The market is segmented into protein supplement, vitamin b12 supplement, vitamin d & calcium supplement, and others. Protein is an essential macronutrient for maintaining normal body functions. Daily protein intake varies with age, gender, and level of daily exercise, but it is essential for maintaining muscle growth and strength throughout one's life. As a result, boosting protein intake in the diet will assist prevent muscle mass loss, hence growing the market.
Growing R&D operations are assisting in discovering the protein dose required to complete the body's protein shortage, and treating sarcopenia will accelerate segmental growth. According to the article "Protein Source and Muscle Health in Older Adults: A Literature Review," which was published in February 2021, increased dietary protein intake of up to 1.2 g/kg body weight/day may help avoid sarcopenia and maintain musculoskeletal health in older adults. Whey as well as soy protein are the most popular high-quality proteins, and consumer demand for new plant-sourced dietary protein choices is increasing.
Furthermore, in April 2022, a research study was launched to investigate the impact of ingesting 12.5g (twice daily) of Blue Whiting Protein Hydrolysates daily in conjunction with exercise for eight weeks on whole body lean mass tissue as well as measures of muscle strength as well as functionality in free-living community-dwelling older adults. The positive findings of this study will increase protein consumption for the treatment of sarcopenia, resulting in segment growth.
Distribution Channel Type
The market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The sarcopenia treatment market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Because of the availability of sophisticated healthcare facilities and technological advances that are projected to fuel the expansion of the sarcopenia treatment market during the forecast period, North America is expected to have a dominating position in the sarcopenia treatment market. Because of the increased frequency of the geriatric population, the existence of multiple important actors, and the country's increasing research and development, the economic burden of sarcopenia-associated disability is being examined in the United States.
For example, according to the survey "Publication Trends for Sarcopenia in the World: A 20-Year Bibliometric Analysis" published online in February 2022, the United States Department of Health and Human Services was the foremost funding organisation that supported 1,604 sarcopenia-related articles, and the United States is the leading country that contributes the most to sarcopenia-related research and development. This enhanced research is expected to result in numerous advancements in the country, boosting the expansion of the country's sarcopenia therapy market.
Research Methodology
This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.
More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.
We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.
Report Features
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
Market structure: Overview, industry life cycle analysis, supply chain analysis.
Market Environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
Market trend and forecast analysis.
Market segment trend and forecast.
Competitive landscape and dynamics: Market share, Product Portfolio, New Product Launches, etc.
Attractive market segments and associated growth opportunities.
Emerging trends.
Strategic growth opportunities for the existing and new players.
Key success factors.
Customization Options
With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:
Company Profiling
Detailed profiling of additional market players (up to three players)
SWOT analysis of key players (up to three players)
Competitive Benchmarking
Benchmarking of key players on the following parameters: product portfolio, geographical reach, regional presence, and strategic alliances
Custom Research: Stratview research offers custom research services across the sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@Stratviewresearch.com
LOADING
LOADING
×
Please enter your contact details. It will allow our analysts to reach out to you.
The major players in the sarcopenia treatment market are GlaxoSmithKline plc, Nestle Health Science, Sanofi S.A., Bayer AG, Novartis AG, Cadila Healthcare Ltd, Eli Lilly and Company.
Because of the availability of sophisticated healthcare facilities and technological advances that are projected to fuel the expansion of the sarcopenia treatment market during the forecast period, North America is expected to have a dominating position in the sarcopenia treatment market.
